Oncolytic viruses are novel and promising therapeutic regimens that promote antitumor efficacy through multimode mechanisms, including direct lysis of tumor cells, release of the tumor antigens and danger signals, induction of immunological cell death, activation of innate and adaptive immune response. In addition, oncolytic viruses can be engineered to express virus‐centered and immune‐centered therapeutic transgenes, further transforming the “cold” tumor into “hot” and enhancing the oncolytic efficacy. Several oncolytic viruses have been engineered and widely used as potential therapeutic agents for many cancers and the therapeutic strategies and effectiveness vary among different types of oncolytic viruses. Finally, oncolytic viruses‐based combination immunotherapy has been practiced in preclinical and clinical studies, and indicated that combination oncolytic viruses with conventional therapy or immunomodulatory agents exerted favorable antitumor efficacy.This article is protected by copyright. All rights reserved

中文翻译：

---

癌症免疫治疗中的溶瘤病毒

溶瘤病毒是新颖且有前途的治疗方案，通过多模式机制促进抗肿瘤功效，包括直接裂解肿瘤细胞、释放肿瘤抗原和危险信号、诱导免疫细胞死亡、激活先天性和适应性免疫反应。此外，溶瘤病毒可以被设计为表达以病毒为中心和以免疫为中心的治疗性转基因，进一步将“冷”肿瘤转化为“热”肿瘤，增强溶瘤功效。几种溶瘤病毒已被设计并广泛用作许多癌症的潜在治疗剂，不同类型的溶瘤病毒的治疗策略和有效性各不相同。最后，基于溶瘤病毒的联合免疫疗法已在临床前和临床研究中得到实践，表明溶瘤病毒与常规疗法或免疫调节剂联合发挥了良好的抗肿瘤功效。本文受版权保护。版权所有